TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38934147
Drug: Ritlecitinib (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib (any dose)
Study: 38934231
Drug: CaHA-CMC(+) injections
Normalized name: CMC 001
DrugBank: CMC 001 (DB05353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaHA-CMC(+) injections
Study: 38934602
Drug: Continuous unfractionated
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous unfractionated heparin (UFH) infusion at 10 to 15 units/kg/h for infants with CRT and 2 to 3 units/kg/h without CRT
Study: 38934602
Drug: Continuous unfractionated
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous unfractionated heparin (UFH) infusion
Study: 38934845
Drug: mRNA-1010 (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1010 (6.25 µg to 200 µg)
Study: 38934845
Drug: mRNA-1010 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1010 (25 µg to 200 µg)
Study: 38934845
Drug: mRNA-1010 (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1010 (6.25 µg to 25 µg)
Study: 38934845
Drug: mRNA-1010 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1010 (50 µg)
Study: 38934914
Drug: Multisession attentional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisession attentional bias modification (ABM) training, details on dosage and duration not specified
Study: 38934966
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) added to intravenous furosemide regimen
Study: 38934966
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to intravenous furosemide regimen
Study: 38934968
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg monthly subcutaneous injections
Study: 38935053
Drug: Nurse-led brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led brief behavioral treatment for insomnia (BBTI)
Study: 38935059
Drug: Fentanyl-test (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl-test (1 mcg/kg fentanyl administration)
Study: 38935125
Drug: Primary tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary tumor resection and systemic treatment (PTR+SYST)
Study: 38935125
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment only (SYST)
Study: 38936466
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 50/25 µg once daily
Study: 38936466
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 50 µg once daily
Study: 38936755
Drug: Low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose colchicine 0.5 mg daily
Study: 38937182
Drug: Four-dose test
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose test group (2-1-1 regimen)
Study: 38937182
Drug: Four-dose control
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose control group
Study: 38937182
Drug: Five-dose control
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-dose control group
Study: 38937182
Drug: Four-dose test
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose test group
Study: 38937310
Drug: Early palliative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early palliative care (EPC) integration, monthly meetings with a palliative care team for 12 months
Study: 38937404
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg initial doses at weeks 0, 2, and 4, followed by CZP 200 mg every 2 weeks or CZP 400 mg every 2 weeks maintenance dosing.
Study: 38937792
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of surgeon's choice
Study: 38937798
Drug: Personalized Citizen
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalized Citizen Assistance for Social Participation (APIC); weekly 3-h personalized stimulation sessions given by a trained volunteer over a 12-month period
Study: 38937803
Drug: Haploidentical CD34+
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical CD34+ enriched and CD45RA-depleted hematopoietic progenitor cell grafts followed by NK-cell infusion
Study: 38937824
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality cue-exposure therapy (VRCET) plus memory-focused cognitive therapy (MFCT)
Study: 38937824
Drug: Picture-based cue-exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picture-based cue-exposure therapy (PCET)
Study: 38938387
Drug: Self-administered SAGE
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered SAGE used during PCP visits
Study: 38939480
Drug: Recommended dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose edoxaban
Study: 38939629
Drug: Organized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organized treatment pathway
Study: 38939828
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day plus cholecalciferol 800 IU/day (RalD)
Study: 38940282
Drug: Apalutamide 240
Normalized name: apalutamide 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide 240 mg/day
Study: 38940373
Drug: Oregovomab plus
Normalized name: Oregovomab
DrugBank: Oregovomab (DB04964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregovomab plus non-platinum-based chemotherapy (pegylated liposomal doxorubicin or paclitaxel)
Study: 38940373
Drug: Non-platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum-based chemotherapy (pegylated liposomal doxorubicin or paclitaxel)
Study: 38940733
Drug: Photobiomodulation Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation Treatment with a Home-Use Device
Study: 38940981
Drug: Ovarian function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian function recovery (OFR) in patients with CIOFF receiving anastrozole treatment.
Study: 38941062
Drug: Metal-on-polyethylene (MoP)
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal-on-polyethylene (MoP) arthroplasty implants
Study: 38941062
Drug: MoP arthroplasty
Normalized name: methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MoP arthroplasty implants
Study: 38941132
Drug: Concurrent validity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent validity of 6MST compared to CPET and 6MWT
Study: 38941376
Drug: Raftlin level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raftlin level ≥ 6.31 ng/mL
Study: 38941599
Drug: Syalox 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syalox 300 Plus (high-molecular-weight hyaluronic acid) administered orally for 8 weeks.
Study: 38942047
Drug: Namilumab 150
Normalized name: sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Namilumab 150 mg subcutaneously at weeks 0, 2, 6, and 10
Study: 38942114
Drug: Elevated Lp(a)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated Lp(a) (≥150 nmol/L)
Study: 38942591
Drug: MIST discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIST discontinuation group (n=27)
Study: 38942592
Drug: Nipocalimab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab (15 mg/kg intravenously every 2 weeks)
Study: 38942693
Drug: Vicriviroc 150
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 150 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks
Study: 38942693
Drug: Vicriviroc 250
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc 250 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks
Study: 38942994
Drug: AAV gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV gene therapy (AP4M1 gene) administered intrathecally
Study: 38943053
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program combining three nutritional workshops and 12 weekly physical activity sessions.
Study: 38943063
Drug: Qualitative evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative evaluation of treatment suitability for CEBA profiles in a small group of PwMS.
Study: 38943192
Drug: Vilobelimab (C5a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilobelimab (C5a inhibitor)
Study: 38943294
Drug: Short messages
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short messages informing relatives during surgery (preparations for surgery have begun, surgery has started, surgery is ongoing, surgery is completed)
Study: 38943664
Drug: Sapanisertib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib (5 mg daily)
Study: 38943928
Drug: Luvadaxistat 50
Normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luvadaxistat 50 mg
Study: 38943928
Drug: Luvadaxistat 125
Normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luvadaxistat 125 mg
Study: 38943928
Drug: Luvadaxistat 500
Normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luvadaxistat 500 mg
Study: 38944045
Drug: Natural cycle
Normalized name: Natural Cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural cycle endometrial preparation
Study: 38944045
Drug: Modified natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified natural cycle endometrial preparation
Study: 38944045
Drug: Artificial cycle
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial cycle endometrial preparation
Study: 38944806
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) for at least 24 months
Study: 38945140
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment targeting systolic blood pressure of less than 120 mm Hg
Study: 38945140
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment targeting systolic blood pressure of less than 140 mm Hg
Study: 38945800
Drug: Furmonertinib combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib combined with carboplatin and pemetrexed for 4 cycles, then furmonertinib and pemetrexed as maintenance therapy (Arm B2)
Study: 38945800
Drug: Furmonertinib combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib combined with carboplatin and pemetrexed for 4 cycles, then furmonertinib and pemetrexed as maintenance therapy plus bevacizumab (Arm B3)
Study: 38945800
Drug: Furmonertinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib monotherapy (Arm B1)
Study: 38946384
Drug: Mini-fluid challenge
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-fluid challenge (MFC) with 100 mL of crystalloids
Study: 38946484
Drug: ABBV-184 (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-184 (0.07 ug/kg initially, with 2- to 3-fold dose increases)
Study: 38946973
Drug: JAK inhibitor
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitor tofacitinib
Study: 38947093
Drug: Xpert HR-CAD4TB
Normalized name: CPERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xpert HR-CAD4TB (sequential negative screening)
Study: 38947093
Drug: CRP-CAD4TB (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP-CAD4TB (sequential negative screening)
Study: 38947093
Drug: Xpert HR-CAD4TB
Normalized name: CPERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xpert HR-CAD4TB (sequential positive screening)
Study: 38947228
Drug: CPX-351 (liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-351 (liposomal daunorubicin and cytarabine) administered at 135 units/m
Study: 38948487
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment plus exercise therapy
Study: 38948487
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture plus exercise therapy
Study: 38949715
Drug: Complete decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete decongestive therapy (CDT) 5 days a week for 3 weeks in MetS group
Study: 38949715
Drug: Complete decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete decongestive therapy (CDT) 5 days a week for 3 weeks in control group
Study: 38949758
Drug: Vupanorsen 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen 80 mg
Study: 38949758
Drug: Vupanorsen 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen 160 mg
Study: 38949813
Drug: Clinician nudge
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician nudge only (active control + weekly peer comparisons)
Study: 38950321
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of induction immunochemotherapy followed by SCRT and the rest four doses (Group B)
Study: 38950376
Drug: Treatment based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment based on voiding diaries (dDAVP for nocturnal polyuria with normal MVV; enuresis alarm for reduced MVV and no nocturnal polyuria)
Study: 38950376
Drug: Randomly allocated
Normalized name: Alloxate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly allocated treatment (dDAVP or alarm)
Study: 38950925
Drug: Niraparib first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib first-line maintenance therapy
Study: 38950931
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (21 mL of 2% lidocaine and 50 μg fentanyl)
Study: 38950991
Drug: Full/near-full optical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full/near-full optical treatment requiring wear for at least half their waking hours for 24 weeks.
Study: 38950991
Drug: Full/near-full optical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full/near-full optical treatment
Study: 38950995
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type A (BoNT-A) treatment at different timings
Study: 38950995
Drug: Rehabilitation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rehabilitation without BoNT-A treatment
Study: 38950997
Drug: Standard inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inactivated quadrivalent influenza vaccine
Study: 38951012
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBM) applied to bilateral knees and lumbar paraspinal points.
Study: 38951699
Drug: Early integration
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early integration of specialised palliative care (SPC) alongside tumour-specific palliative treatment
Study: 38951699
Drug: Tumour-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour-specific treatment alone (Control)
Study: 38951777
Drug: SM-ART intervention
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-ART intervention (six weekly sessions of 60 to 90 minutes)
Study: 38951902
Drug: CBD oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD oral solution
Study: 38952209
Drug: Benzodiazepine discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine discontinuation programme
Study: 38952554
Drug: Regorafenib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (oral, maximum daily dose of 160 mg for weeks 1-3 of each 4-week cycle)
Study: 38952672
Drug: Short-course oxaliplatin-based
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB)
Study: 38952884
Drug: Betamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (2 doses of 12mg intramuscular)
Study: 38952884
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 doses of 12mg intramuscular)
Study: 38953034
Drug: Icanbelimod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icanbelimod 0.5 mg
Study: 38953034
Drug: Icanbelimod (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icanbelimod (various doses)
Study: 38953542
Drug: Higher adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher adalimumab induction dose
Study: 38953600
Drug: Standard adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard adalimumab dosing regimen
Study: 38953934
Drug: High FDG
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High FDG Ki group (n=8, Ki > 2.779 ml/min/100 g)
Study: 38953934
Drug: Low FDG
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low FDG Ki group (n=7, Ki ≤ 2.779 ml/min/100 g)
Study: 38953936
Drug: Video-based cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-based cervical stabilization exercises, performed three times a week for six weeks in addition to routine medication.
Study: 38953936
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued routine medication only.
Study: 38954226
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg SC at baseline, weeks 1 and 2, and every 2 weeks thereafter until week 16
Study: 38954226
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg SC
Study: 39399879
Drug: TV-46000 once
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-46000 once monthly (q1m)
Study: 38954475
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (3 sessions over 10 weeks)
Study: 38954680
Drug: Relugolix combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix combination therapy (Myfembree®) after surgical myomectomy
Study: 38954692
Drug: Probiotic capsule
Normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsule (Lactobacillus salivarius WB21, 6.7 x 108 CFU, xylitol 280mg, 3 times a day for 14 days)
Study: 38954782
Drug: TK216 administered
Normalized name: TK216
DrugBank: TK216 (DB17414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TK216 administered as a 14-day continuous infusion
Study: 38954834
Drug: Genetic deletion
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic deletion of JAM-C (Junctional Adhesion Molecule-C) in leukemic stem cells (LSCs)
Study: 38954874
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (NS)
Study: 38954899
Drug: nab-paclitaxel, gemcitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel, gemcitabine, and oxaliplatin (first-line treatment)
Study: 38954929
Drug: MI-Walk intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-Walk intervention (motivational enhancement therapy with 3 counseling sessions, Fitbit Charge 2, exercise diaries, telephone follow-up, motivational emails, optional walking groups)
Study: 38955178
Drug: Oral terameprocol
Normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terameprocol at 1,200 mg/day (n=3)
Study: 38955178
Drug: Oral terameprocol
Normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terameprocol at 2,400 mg/day (n=6)
Study: 38955178
Drug: Oral terameprocol
Normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terameprocol at 3,600 mg/day (n=3)
Study: 38955178
Drug: Oral terameprocol
Normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terameprocol at 6,000 mg/day (n=2)
Study: 38955178
Drug: Oral terameprocol
Normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terameprocol at 6,000 mg/day in fed state (n=4)
Study: 38955368
Drug: Plasma solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma solution
Study: 38955554
Drug: High Troponin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Troponin I (TnI > 6 ng/L)
Study: 38955554
Drug: High C-reactive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High C-reactive protein (CRP > 2 mg/L)
Study: 38956594
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg microcrystalline cellulose (MCC) placebo